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Abstract
Blockade of tumour necrosis factor (TNF) is an effective
treatment in rheumatoid arthritis (RA), but both non-responders
and partial responders are quite frequent. This suggests that
other pro-inflammatory cytokines may be of importance in the
pathogenesis of RA and as possible targets for therapy. In this
study we investigated the effect of TNF blockade (infliximab) on
the synovial expression of IL-15 in RA in relation to different cell
types and expression of other cytokines, to elucidate whether or
not IL-15 is a possible target for therapy, independently of TNF
blockade. Two arthroscopies with multiple biopsies were
performed on nine patients with RA and knee-joint synovitis
before and after three infusions of infliximab (3 mg/kg). Synovial
biopsies were analysed with immunohistochemistry for
expression of IL-15, TNF, IL-1α, IL-1ß and IFN-γ, and for the cell
surface markers CD3, CD68 and CD163. Stained synovial
biopsy sections were evaluated by computerized image
analysis. IL-15 expression was detected in all synovial biopsies
taken at baseline. After infliximab therapy, the expression of IL-
15 was increased in four patients and reduced in five. Synovial
expression of IL-15 was not correlated with any CD marker or
with the presence of any other cytokine. Synovial cellularity was
decreased after 8 to 10 weeks of treatment with a significant
reduction of the CD68-positive synovial cells, whereas no
significant change was seen in the number of CD3-positive T
cells and CD163-expressing macrophages. The number of TNF-
producing cells in the synovial tissue at baseline was correlated
with a good response to therapy. Thus, in this study the synovial
expression of IL-15 in RA was not consistently influenced by
TNF blockade, being apparently independent of TNF expression
in the synovium. Consequently, we propose that IL-15 should
remain as a therapeutic target in RA, regardless of the response
to TNF blockade.
Introduction
Blockade of tumour necrosis factor (TNF) in active rheumatoid
arthritis (RA) is effective in reducing disease activity [1] and in
stopping joint destruction [2]. However, both non-responders
and partial responders to TNF blockade are frequent [1], indi-
cating a considerable influence of other pro-inflammatory
cytokines beside TNF in perpetuating inflammation in RA.
IL-15 has been identified as a pro-inflammatory cytokine of
potential importance in the pathogenesis of RA [3].
In the synovial membrane of patients with RA, there is a sub-
stantial expression of IL-15, predominantly expressed in mac-
rophages but also in fibroblast-like synoviocytes and
endothelial cells [3-5]. IL-15 has been described as inducing
chemotaxis and proliferation of T cells and acting through a
cell-contact-dependent mechanism between memory T cells
and macrophages [6]. IL-15 may also contribute to an
increased production of the pro-inflammatory cytokines TNF,
IFN-γ and IL-17 in T cells [7]. Taken together, these findings
suggest that an IL-15-dependent pro-inflammatory feedback
loop may be created in the inflamed synovium, in which IL-15
stimulates the production of TNF, IFN-γ and IL-17, which in
ACR = American College of Rheumatology; DAS28 = Disease Activity Score counted on 28 joints; IFN = interferon; IL = interleukin; mAb = mono-
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turn stimulate the further production of IL-15, IL-8 and IL-6 in
fibroblast-like synoviocytes [7,8].
An additional pivotal role of IL-15 as a link between the innate
and adaptive immune system was recently suggested from the
observation that activated T cells express Toll-like receptor 2,
a co-stimulatory receptor that acts together with IL-15 in main-
taining T cell activation [9].
Because IL-15 might have a central role in sustaining inflam-
mation in RA, this cytokine has been considered as a potential
therapeutic target in RA. Both a soluble fragment of the IL-15-
receptor  α-chain and an antagonistic IL-15 mutant/Fcγ2a
fusion protein have been reported to suppress the develop-
ment of collagen-induced arthritis in murine models [10,11].
These beneficial effects were accompanied by both a reduced
production of TNF, IL-1ß, IL-6 and IL-17 in the inflamed joints
of the treated animals and a decreased frequency of T cells
reactive to anti-collagen II [11].
Finally, and most importantly, a phase I/II trial with an antibody
blocking IL-15 given to RA patients was recently reported with
promising results [12].
An important question in relation to the development of future
therapies targeting IL-15 is how the expression of this cytokine
will be affected by existing therapies, including TNF blockade.
In this study we therefore investigated the effect of infliximab,
a TNF-blocking antibody, on the synovial expression of IL-15 in
relation to different cell types and the expression of other
cytokines.
Materials and methods
Patients, treatment and clinical assessments
Nine patients (seven females, two males) with RA (seven pos-
itive for rheumatoid factor, and two negative) according to the
American College of Rheumatology (ACR) criteria, and arthri-
tis of the knee joint, were recruited for this study. All patients
were assessed for disease activity at baseline and at three
months, with the Disease Activity Score counted on 28 joints
(DAS28). ACR response criteria were also used to record the
result of the therapy. Functional capacity was recorded with
the health assessment questionnaire. The median DAS28 at
inclusion was 5.95 (range 4.83 to 7.91), despite treatment
with methotrexate (7.5 to 20 mg per week). The dose of meth-
otrexate was stable during the study and at least one month
before the first arthroscopy. Four patients received pred-
nisolone in an equally stable dose of not more than 10 mg per
day. The median age was 57 years (range 25 to 69) and the
median disease duration was 6 years (range 0.5 to 18). The
median duration of the current episode of arthritis in the knee
was 17.5 days (range 3 to 365, lacking data for one patient).
Three intravenous infusions of infliximab (3 mg/kg; Centocor
B.V, Leiden, The Netherlands) were given in accordance with
the recommended standard treatment protocol, with the first
infusion given 1 to 21 days after the first arthroscopy and the
subsequent infusions given after 2 and 6 weeks.
Informed consent was obtained from all patients, and the study
was approved by the local ethics committee at the Karolinska
University Hospital.
Synovial biopsies, immunohistochemistry and 
computer-assisted image analysis
An arthroscopy with multiple biopsies of the knee joint was
performed in all patients 1 to 21 days before the first infusion.
A second arthroscopy was performed at 8 to 10 weeks
(median 9 weeks) after the first infusion. Total knee joint
replacement surgery was considered as a substitute for the
second arthroscopy in patient no. 7. The same physician (EaK)
performed all arthroscopies. At the first arthroscopy, biopsies
were predominantly taken from areas of the synovial tissue
with signs of maximal macroscopic inflammation, from the car-
tilage-pannus junction and from synovial villi. The biopsy site
was documented photographically and at the second arthros-
copy the biopsies were taken from the same area as the first
biopsies. The biopsies were snap-frozen within 2 minutes in
liquid isopentane and stored at -70°C until sectioned. Serial
cryostat sections (7 µm) were fixed for 20 min with 2% (v/v)
formaldehyde and stored at -70°C.
Several biopsies were taken to secure sufficient material. For
each of the nine patients, the biopsy with the best morphology
was selected for subsequent immunohistochemical staining.
The staining was always performed in pairs before and after
treatment infliximab, allowing a pairwise comparison.
Two anti-(human IL-15) mAbs were used, one neutralizing (B-
E29) and one non-neutralizing (B-T15; both from Diaclone
SAS, Besancon, France). The staining procedure has been
described previously [13]. Biopsy specimens were also ana-
lysed for the presence of the cytokines IL-1α, IL-1ß, IL-2, IL-4,
IFN-γ, TNF mAb1 and mAb11, and for the presence of the cell
surface markers CD3, CD19, CD20, CD68 and CD163, as
described previously [14]. In addition, for TNF a new neutraliz-
ing IgG1γ mAb, 2C8, was used (Biodesign, Maine, USA).
Negative controls with isotype-matched IgG were included for
each marker.
Two evaluators, blinded to the origin and order of the sections,
performed a semi-quantitative analysis of the expression of
cytokines and cell surface markers, considering the number of
positive cells in the stained sections. TNF mAb1 and mAb11
and IFN-γ were scored with a semi-quantitative four-point
scale as follows: 0 = no positive cells, 1 = 1 to 10 positive
cells, 2 = 11 to 100 positive cells, and 3 = more than 100 pos-
itive cells [15]. Cell surface markers (CD3, CD68 and CD163)
were scored with another semi-quantitative four-point scale:
0 = no infiltration, 1 = minimal infiltration, 2 = moderateAvailable online http://arthritis-research.com/content/8/1/R18
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infiltration, and 3 = marked infiltration [16]. In the blinded man-
ner described, stained synovial biopsy sections were evalu-
ated by computerized image analysis, in which the area of
positive staining was expressed as a percentage of the total
tissue area, for IL-15 neutralizing and non-neutralizing antibod-
ies, IL-1α, IL-1ß and TNF mAb 2C8. Analysis of an entire tis-
sue section typically involved 25 to 210 (median 70)
microscope fields, corresponding to an area of 0.7 to 9.1 mm2
(median 2.9 mm2) at a magnification of × 250.
To evaluate which cells were predominantly expressing IL-15,
double staining was performed on samples from two of the
patients (nos 3 and 5) for IL-15 neutralizing antibody and IL-15
non-neutralizing antibody, together with CD markers CD3,
CD19/20, CD68 and CD163.
Statistical analysis
A Mann-Whitney U test was used for the analysis of differ-
ences between groups. Wilcoxon's signed-rank test was used
for the analysis of matched pairs. A Spearman rank correlation
test was used for correlations between variables. p < 0.05
was considered statistically significant.
Results
Patients and response to treatment
The individual DAS28 values are presented in Table 1. Median
DAS28 scores were reduced from 5.95 to 4.41 (p < 0.01), the
median tender joint count from 10 to 3 (p < 0.05), the median
swollen joint count from 14 to 2 (p < 0.01) and the median C-
reactive protein from 34 mg/L to 19 mg/L (p = 0.08), and the
median health assessment questionnaire improved from 1.63
to 1.38 (p  < 0.05). Two patients fulfilled ACR 70%, one
patient fulfilled ACR 50%, three patients fulfilled ACR 20%
and three patients were non-responders according to the
ACR criteria at clinical evaluation after treatment with three
infusions of infliximab (Table 1).
Table 1
Individual quantification of synovial stainings of cytokines, individual DAS28 values and ACR response rates
Patient Week TNFa IFN-γa IL-1αb IL-1ßb IL-15 neutr.b IL-15 non-neutr.b DAS28 ACR response (%)
1 0 0 1 0.9 0.5 0.8 5.1 6.71
9 0 1 0.1 0.8 3.2 13.2 6.34 0
2 0 0 2 2.5 0.4 1.5 3.4 6.00
9 0 0 1.2 0.3 2 12.6 4.43 20
3 0 1 1 0.9 7.3 0.3 15.1 7.91
9 0 0 0.4 0.1 0 2.1 5.41 50
4 0 0 1 1.2 0.1 0.1 0.6 4.94
9 0 2 2.1 33.1 4.6 7.1 4.41 20
5 0 1 1 0.1 0.6 11.3 3.6 5.95
9 1 1 2.1 0 1.2 13 2.90 70
6 0 1 1 0.2 2.5 2.7 0.4 7.39
9 0 1 0.8 4.4 5.4 7.5 1.79 70
7 0 0 0 0.8 0.7 4.4 2.5 4.83
9 0 0 0.1 0.1 0 0 4.23 0
8 0 0 0 2.1 0.5 9.5 16.7 5.64
9 0 0 3.3 1.1 6.6 15.1 4.73 0
9 0 0 0 4.9 4.3 4.6 11 5.62
9 1 0 3.7 4.4 2.8 6 3.91 20
Individual quantification of stainings of synovial samples from nine patients with rheumatoid arthritis, before and after treatment with infliximab. aA 
semi-quantitative analysis was performed for tumour necrosis factor (TNF; mAb1 and mAb11) and IFN-γ, for which a semi-quantitative four-point 
scale was used: 0 = no positive cells, 1 = 1 to 10 positive cells, 2 = 11 to 100 positive cells, and 3 = more than 100 positive cells. bA 
computerized image analysis was performed for IL-1a, IL-1ß IL-15 neutralizing antibody and IL-15 non-neutralizing antibody; values are median 
percentages of the stained tissue area, with ranges in parenthesis.
Individual DAS28 values and ACR response results are presented. ACR, American College of Rheumatology; DAS28, Disease Activity Score 
counted on 28 joints.Arthritis Research & Therapy    Vol 8 No 1    Ernestam et al.
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Immunohistochemical analysis
CD-markers
The results of the semi-quantitative analysis of the staining for
CD markers are summarized in Table 2. A significant decrease
in the CD68-positive synovial cells (p = 0.018) was observed
in the second biopsies in comparison with the initial ones,
whereas the numbers of CD3-positive T cells and CD163-
positive activated macrophages were not significantly
changed, although there was a trend towards a reduction.
Tissue distribution of staining for IL-15
IL-15-positive cells were found in the synovial lining and sub-
lining layer as well as in endothelial cells (Figure 1) as
described previously [3,4]. Positive intracellular staining, indi-
cating IL-15-producing cells, was detected predominantly in
the lining layer but also in some endothelial cells (Figure 1a).
Double immunofluorescence staining, performed for two of
the patients, revealed co-expression between IL-15, analysed
with the neutralizing antibody, and CD163 (macrophages)
(Figure 2). There was no correlation between the expression
of the cytokines investigated and the presence of cells
expressing CD3 (T cells) and CD68 (macrophages).
Staining for cytokines before and after treatment with 
infliximab
The inter-individual variability in synovial staining was high for
the cytokines IL-15, IL-1α, IL-1ß, IFN-γ and TNF, shown in
Table 1. The results of both the semi-quantitative analysis and
the computerized image analysis of the immunohistochemical
staining for different cytokines are shown in Table 2. Positive
staining for IL-15 was seen in all synovial biopsies at baseline.
After treatment with infliximab, the area that stained positive for
the neutralizing anti-IL-15 antibody was increased in four
patients and decreased in five (Figure 3). In five patients the
area stained with the non-neutralizing anti-IL-15 antibody
increased and in three patients the area decreased (data not
shown). The number of cells that stained positively with the
anti-TNF antibody 2C8 was considerably larger than the
number of cells that stained positively with the anti-TNF anti-
bodies mAb1 and mAb11.
Correlations between clinical parameters and synovial 
stainings for cytokines
There was no correlation between age, disease duration,
health assessment questionnaire and the area or number of
cells that stained positively for any of the different cytokine
antibodies before and after treatment with infliximab. At base-
line, the area that stained positively with the anti-TNF antibody
2C8, analysed by computer image analysis, was significantly
correlated with short disease duration (p < 0.05). At baseline,
the number of cells that stained positively with the anti-TNF
antibodies mAb1 and mAb11, analysed by semi-quantitative
analysis, was exclusively seen in the patients who fulfilled at
least ACR 50% at 3 months (p < 0.05) (Fig. 4), whereas all
sections from the other patients were negative for these two
antibodies.
Discussion
A major finding in the present study was that the expression of
IL-15 in the synovial tissue of patients with RA was not
affected by treatment with three infusions of infliximab. IL-15
was detected at baseline in all synovial biopsies; after treat-
ment with infliximab the change in expression diverged, with-
out any correlation with clinical parameters or the expression
of other cytokines. Further, we found a co-expression of IL-15
and CD163 when analysed with double staining, indicating
that IL-15 in the RA synovial membrane is predominantly pro-
duced by macrophages.
The sampling of biopsies was done in a clinical setting, intro-
ducing potential bias in the timing of the arthroscopy in relation
to the infusion of infliximab. However, previous studies [17,18]
indicate that the minor time variations between samplings and
infusions in our study did not introduce any bias. Immunohisto-
chemistry with the saponin method is a well established
Table 2
Synovial expression of CD markers and cytokines before and 
after treatment with infliximab
Week 0 Week 9 P
CD3a 2 (0–3) 2 (0–2.5) Ns
CD68a 2.5 (1–3) 1 (0–2) 0.02
CD163a 1.5 (0–3) 1.5 (0–2) Ns
TNF mAb1 and mAb11a 0 (0–1) 0 (0–1) Ns
TNF 2C8b 0.25 (0–5.5) 0.3 (0–17.4) Ns
IFN-γa 1 (0–2) 0 (0–2) Ns
IL-1αb 0.9 (0.1–4.9) 1.2 (0.1–3.7) Ns
IL-1ßb 0.6 (0.1–7.3) 0.8 (0–33.1) Ns
IL-15 neutralizingb 2.7 (0.1–11.3) 2.8 (0–6.6) Ns
IL-15 non-neutralizingb 3.6 (0.4–16.7) 7.5 (0–15.1) Ns
Synovial expression of CD markers (CD3 (T cells), CD68 
(macrophages) and CD163 (fibroblasts)) and cytokines (IL-1a, IL-1ß, 
IL-15 neutralizing antibody, IL-15 non-neutralizing antibody, tumour 
necrosis factor (TNF; mAb1 and mAb11) and IFN-γ) was measured 
before treatment and after a median of 9 weeks of treatment with 
infliximab in patients with rheumatoid arthritis. aA semi-quantitative 
analysis was performed for the CD markers CD3, CD68 and CD163. 
Values are medians of the score for numbers of positive stained cells 
with ranges in parenthesis; a semi-quantitative four-point scale was 
used: 0 = no infiltration, 1 = minimal infiltration, 2 = moderate 
infiltration and 3 = marked infiltration. A semi-quantitative analysis of 
cytokines, TNF (mAb1 and mAb11) and IFN-γ was also performed. 
Values are medians of the score for numbers of positive stained cells, 
with ranges in parenthesis; a semi-quantitative four-point scale was 
used: 0 = no positive cells, 1 = 1 to 10 positive cells, 2 = 11 to 100 
positive cells, and 3 = more than 100 positive cells. bA computerized 
image analysis was performed for IL-1α, IL-1ß, IL-15 neutralizing 
antibody and IL-15 non-neutralizing antibody; values are median 
percentages of the stained tissue area, with ranges in parenthesis. 
ns, not significant.Available online http://arthritis-research.com/content/8/1/R18
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method for detecting the intracellular presence of cytokines by
neutralizing antibodies and for further quantification by compu-
terized image analysis. To confirm the staining, a negative
control was used for all antibodies. IL-15 production by mono-
nuclear cells, which had been primed to produce IL-15, was
entirely blocked by both IL-15 neutralizing and IL-15 non-neu-
tralizing antibodies detecting IL-15, thereby demonstrating the
specificity of the staining.
The observation of an overall decrease in synovial cellularity
after TNF blockade is consistent with previous studies [14,19-
21]. Our finding that the synovial infiltration of mononuclear
cells decrease significantly after treatment with infliximab (3
mg/kg), whereas T cells show only a decreasing trend, has
also been reported previously [20]. Interestingly, TNF-produc-
ing cells, detected by TNF neutralizing antibodies mAb1 and
mAb11, were exclusively seen in patients who subsequently
responded well to infliximab with at least an ACR 50%
response. Although the number of patients studied in this
respect was small, the results are in concordance with those
of a previous study of shorter duration [14]. In addition, our
results on the effects of infliximab on synovial cellularity and
the expression of TNF mAb1 and mAb11, IL-1α and IL-1ß are
in good agreement with previous published studies [14,20].
It is noteworthy that the results of staining with the TNF-bind-
ing antibody 2C8 differed from those obtained with mAb1 and
mAb11 in the sense that 2C8 shows rather abundant binding
to extracellular material adjacent to cells that are intracellularly
stained with this antibody. In addition, more cells are stained
with 2C8 than with mAb1 and mAb11, indicating that staining
with 2C8 is more sensitive than staining with mAb1 and
mAb11, used previously by our group [13-15]. The specificity
of the 2C8 antibody for TNF nevertheless seems to be high,
because the positive staining was blocked totally by a
recombinant TNF. We therefore assume that both sets of anti-
TNF antibodies are specific but that they display different sen-
sitivity and possibly also differences in binding to intracellular
TNF only (mAb1 and mAb11) or to both intracellular and extra-
cellular TNF (2C8). It is thus of interest in a clinical setting,
such as that in the present paper, to describe staining patterns
and results for both sets of anti-TNF antibodies. The fact that
the mAb1 and mAb11 antibody-derived TNF stainings were
able to predict a good clinical response, whereas the 2C8
antibody staining was not, calls for further studies with differ-
ent methods to quantify TNF and other cytokines in synovial
tissues.
The most important finding in the present study is the observa-
tion of the presence of IL-15 in synovial tissues both before
and after TNF blockade. IL-15 is a pro-inflammatory cytokine
with the potential to both induce and maintain inflammation
[3,6,7]. The fact that the overall staining for IL-15 did not
change during TNF blockade and that IL-15 was present in the
Figure 1
IL-15 is present in synovial tissue in rheumatoid arthritis before and after treatment with infliximab IL-15 is present in synovial tissue in rheumatoid arthritis before and after treatment with infliximab. Sections of synovial biopsy tissue from patient no. 
5 show diaminobenzidine staining (haematoxylin counterstained) for IL-15 neutralizing antibody before (a) and after (b) treatment with infliximab, and 
for IL-15 non-neutralizing antibody before (c) and after (d) treatment with infliximab. In (a) and (c) solid arrows indicate synovial lining layer and dot-
ted arrows indicate endothelial cells. Original magnification × 250.Arthritis Research & Therapy    Vol 8 No 1    Ernestam et al.
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inflamed joints of all patients suggests that targeting of IL-15
is an interesting potential therapy in RA irrespective of previ-
ous or concomitant therapy with TNF blockade. In a more
biological context, the present result also suggests that the IL-
15-dependent expansion and maintenance of memory T cells
are independent of TNF blockade. This notion is supported by
a report in which either TNF or IL-15 could induce the expres-
sion of natural killer cell receptor NKG2D on auto-reactive
CD4+CD28- T cells [22], and that these cells may contribute
to the self-perpetuating inflammation in RA. Thus, TNF and IL-
15 may, at least in this context, act in parallel and therefore a
blockade of TNF can be insufficient as long as IL-15 is
present.
Conclusion
Our study suggests that blockade of IL-15 might provide an
attractive treatment as an alternative to TNF blockade in RA,
Figure 2
Co-expression of CD163 (macrophages) and IL-15 in the synovial  tissue Co-expression of CD163 (macrophages) and IL-15 in the synovial tis-
sue. Immunofluorescence staining of synovial tissue in rheumatoid 
arthritis of CD163 (a) and IL-15 neutralizing antibody (b) and double 
staining with CD163 and IL-15 (c). Original magnification × 250.
Figure 3
Expression of IL-15 before and after treatment with infliximab Expression of IL-15 before and after treatment with infliximab. Shown is 
the expression of IL-15, analysed with the IL-15 neutralizing antibody, in 
the synovial tissue of nine patients with rheumatoid arthritis before and 
after treatment with infliximab. The percentage of positively stained tis-
sue area, analysed by computerized image analysis, is presented. No 
significant difference was observed.
Figure 4
TNF-producing cells in a patient with RA with a subsequent good  response to infliximab TNF-producing cells in a patient with RA with a subsequent good 
response to infliximab. Sections of synovial biopsy tissue from patient 
no. 6 before (a) and after (b) treatment with infliximab show diami-
nobenzidine staining (haematoxylin counterstained) for TNF neutralizing 
antibodies mAb1 and mAb11. Original magnification × 250.Available online http://arthritis-research.com/content/8/1/R18
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able to function both in patients with low baseline synovial
expression of TNF and in patients with an unsatisfactory
response to TNF blockade. We also provide additional
tentative evidence that the presence and production of TNF in
RA joints may be a predictive feature as to whether the patient
will respond favourably to TNF blockade.
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